Tag:

Roche

Latest Headlines

Latest Headlines

Hospira wins Herceptin patent suit in U.K., paving way for biosim

Hospira is one step closer to selling a Herceptin biosimilar in Britain. The U.S.-based drugmaker persuaded a U.K. court to overturn two Roche patents on the drug. And that means, as of now, Herceptin (trastuzumab) could be open to biosim competition when its main patent expires July 28.

UPDATED: Cochrane study: Stockpiling Tamiflu, Relenza was $2B 'thrown down the drain'

Just weeks after Roche released data backing its claim that its hit drug Tamiflu saved lives during the H1N1 swine flu epidemic of 2009, a new study finds no evidence that the product stops the spread of the flu or reduces its complications.

French watchdogs raid Novartis, Roche in Lucentis antitrust probe

The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.

Meet Spero, a biotech hopeful with Roche's blessing and a novel antibiotic

With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria amid an antibiotic sea change in the industry.

Roche jumps into epigenetics with deal for Oryzon's leukemia hopeful

pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.

Roche snags diagnostics outfit IQuum in $450M deal

Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire Marlborough, MA-based IQuum for $275 million up front and up to $175 million in milestone-based payments.

Lilly, Pfizer partner with Lieber Institute on brain research

The Lieber Institute for Brain Development is partnering with Astellas, Eli Lilly, Lundbeck, Pfizer and Roche to launch an early-stage research consortium to study the genetic mechanisms at work in brain disorders.

Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal

John Reed's Basel-based pRED group at Roche has struck its first epigenetics deal, snapping up rights to Barcelona-based Oryzon's orphan cancer blocker ORY-1001, now being studied in the clinic for acute myeloid leukemia.

Roche's Ventana pairs with Genmab on yet another companion Dx deal

Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.

British cost watchdog backtracks again on Roche's Tarceva

After intitially recommending Roche's targeted cancer drug Tarceva for use by Britain's National Health Service, the U.K.'s National Institute for Health and Care Excellence said in February it was reviewing the recommendation. Now, it looks likely to revert back to its original stance--a reversal of fortune the Swiss drugmaker is pleased with.